BUZZ-Moderna rises after FDA advisers back flu vaccine

Moderna

Moderna

MRNA

0.00

** Shares of vaccine maker Moderna MRNA.O rise 4.1% to $64.26

** U.S. FDA advisers unanimously back approval of MRNA's flu vaccine, mFlusiva, for adults aged 50 and older

** All nine panel members vote in favor, saying the shot's benefits outweigh its risks in adults aged 50-64 as well as those aged 65 and above

** Under former FDA Commissioner Marty Makary, the health regulator had rejected Moderna's initial application for the shot before reversing course

** Including session's move, MRNA up 118.1% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.